Greenwich LifeSciences, Inc. (GLSI) Form 10-K — Jun 1, 2026
Greenwich LifeSciences reported a net loss of $19.4 million for the fiscal year ended December 31, 2025, widening from $17.4 million in the prior year, with an accumulated deficit reaching $87.1 million. The company, which has no revenue, explicitly states that its existing cash is insufficient to complete the development of its lead product candidate GP2 or to file for regulatory approval, which it estimates will cost over $30 million. The filing highlights significant liquidity risks, noting that the company will need to raise substantial additional capital to continue operations and may be forced to delay or eliminate product development programs if funding is not secured.
Key figures
- Federal NOLs
- 44200000
- Shares Outstanding
- 14678208
- Market Value Non Affiliates
- 56000000
- Estimated BLACost
- >$30 million
- Stock Price As Of June2025
- 9.07
Price after filing
Close on the filing date to close N calendar days later (from $28.51). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.